NCT03965988 Docosahexaenoic Acid on Breath Holding Spells in Children
| NCT ID | NCT03965988 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Sherief Abd-Elsalam |
| Condition | Breath Holding Attack |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2018-05-01 |
| Primary Completion | 2028-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 60 participants in total. It began in 2018-05-01 with a primary completion date of 2028-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
DHA on Breath Holding Spells
Eligibility Criteria
Inclusion Criteria: * Children with newly diagnosed sprlls Exclusion Criteria Other treatment as iron and piracetam
Contact & Investigator
Amira Darwish, Lecturer
PRINCIPAL INVESTIGATOR
Tanta University - Faculty of Medicine
Frequently Asked Questions
Who can join the NCT03965988 clinical trial?
This trial is open to participants of all sexes, aged 1 Month or older, up to 5 Years, studying Breath Holding Attack. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03965988 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 60 participants.
Is NCT03965988 currently recruiting?
Yes, NCT03965988 is actively recruiting participants. Contact the research team at sheriefabdelsalam@yahoo.com for enrollment information.
Where is the NCT03965988 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT03965988 clinical trial?
NCT03965988 is sponsored by Sherief Abd-Elsalam. The principal investigator is Amira Darwish, Lecturer at Tanta University - Faculty of Medicine. The trial plans to enroll 60 participants.